Case studies
Pharma & Biotech Roche

Roche Was Making Market Decisions on Data That Arrived Too Late to Act On

Medical reps were gathering valuable intelligence every single day — on prescribing patterns, drug effectiveness, and regional demand. That intelligence was evaporating before it could reach the people who needed it. We built the system that caught it.

Real-time market intelligence — replacing a reporting cycle that was always days behind
Unified cross-market database — structured data replacing unstructured rep notes for the first time
Decisions supported by evidence — commercial strategy informed by field data, not quarterly surveys
Client
Roche (global pharma & biotech)
Engagement type
Data strategy & mobile platform
Core outcome
Real-time field intelligence system
Markets covered
Multi-market deployment

Roche's medical representatives are among the best-informed people in any market they operate in. They meet doctors and pharmacists daily. They know which drugs are being prescribed and why, which treatments are working, and what the gaps are between what's available and what patients actually need. None of that intelligence was reaching Roche's commercial and marketing teams in a usable form. The data was being gathered — it just wasn't being captured. By the time that information was aggregated, filtered, and presented to the people making positioning decisions, the market had moved.

The diagnostic started not with technology but with the people doing the work. We mapped exactly what Roche’s reps were capturing, in what format, how frequently, and what happened to that information after it left the field. The finding was consistent across markets: the problem wasn’t that reps weren’t gathering data — it was that there was no structured home for it to go to.

We ran UX workshops directly with the rep population to understand how they worked in the field — the constraints of their schedules, the devices they carried, the conditions under which they were entering information. A system they would actually use had to be frictionless in those conditions. Complex data entry during a hospital visit isn’t a workflow — it’s an obstacle.

The result was a mobile-first data collection system designed around the rep’s actual daily rhythm: quick structured inputs during or immediately after doctor visits, synced automatically to a centralised platform that aggregated, structured, and surfaced the data for commercial and marketing teams in real time.

The shift wasn’t just operational — it was strategic. Roche’s commercial teams went from making decisions based on aggregated quarterly summaries to having a structured, searchable database of field intelligence that updated continuously. The same reps, the same visits, the same conversations — but now every one of those interactions was adding to a system that could be queried, analysed, and acted upon.

For the first time, Roche had a structured, cross-market database of prescribing patterns, doctor specialisations, and drug effectiveness feedback — built from field data, not surveys. Marketing and commercial strategy teams could query the platform and receive structured intelligence the same day it was gathered. The platform included a feedback loop that let Roche test new data collection approaches quickly, evaluate output quality, and iterate without a multi-month IT project each time.

What we delivered

What permanently changed.

Intelligence that arrives before the decision window closes
Commercial and marketing teams no longer work with data that's already historical. Field intelligence arrives structured, queryable, and actionable within hours of being gathered — not weeks.
A field force that contributes to strategy, not just sales
The reps' daily intelligence — previously evaporating into notes and memory — now feeds directly into commercial strategy. The organisation learns from the field rather than just deploying to it.
A platform that works the same way in every market
Multi-market pharma operations are complex by design — regulations, languages, and workflows diverge. The platform was built once with all of that complexity accommodated, not replicated per country.

We don't put anything on the roadmap we can't defend to your CFO. Every initiative must justify at least 0.5 FTE in savings. If it can't — it doesn't proceed.

CB
Cezary Bielecki
CEO & Founder, Digital Forms
Start the conversation

Ready for a
different kind of conversation?

Start with a free diagnostic. We map your biggest operational bottlenecks and attach a real number to each one — in four weeks. No obligation. No sales deck. You keep the findings regardless.

Response within one business day. Every message is read personally by Cezary or Przemek — not a sales team.
Free diagnostic call — 30 minutes. We'll identify your top operational bottlenecks before we discuss any engagement.
CFO-ready output. Every recommendation comes with a number attached. If we can't defend it to your CFO, we won't propose it.
Next case study — Pharma & Biotech
12× Innovation Output at Roche